[1]曹琼丹,杨育红,于胜男,等.黄芪甲苷对Ⅰ型糖尿病大鼠心肌细胞PGC-1α和NRF-1表达的影响[J].中国药理学通报,2015,(08):1096-1100.[doi:10.3969/j.issn.1001-1978.2015.08.014]
 CAO Qiong-dan,YANG Yu-hong,YU Sheng-nan,et al.Effect of astragaloside IV on expression of PGC-1α and NRF-1 in myocardial cells of typeⅠdiabetic rat[J].Chinese Pharmacological Bulletin,2015,(08):1096-1100.[doi:10.3969/j.issn.1001-1978.2015.08.014]
点击复制

黄芪甲苷对Ⅰ型糖尿病大鼠心肌细胞PGC-1α和NRF-1表达的影响()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2015年08期
页码:
1096-1100
栏目:
论 著
出版日期:
2015-08-15

文章信息/Info

Title:
Effect of astragaloside IV on expression of PGC-1α and NRF-1 in myocardial cells of typeⅠdiabetic rat
作者:
曹琼丹杨育红于胜男鲁美丽张素萍韩镕徽胡 进
辽宁医学院心脑血管药物研究重点实验室,辽宁 锦州 121001
Author(s):
CAO Qiong-danYANG Yu-hongYU Sheng-nanLU Mei-liZHANG Su-ping HAN Rong-huiHU Jin
Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning Province, Drug Research Institute,Liaoning Medical University, Jinzhou Liaoning 121001,China
关键词:
黄芪甲苷 糖尿病心肌病 PGC-1α NRF-1 线粒体 能量代谢
Keywords:
astragaloside IV diabetic cardiomyopathy PGC-1α NRF-1 mitochondria energy metabolism
分类号:
R-332; R284.1; R329.24; R329.411; R587.102.2
DOI:
10.3969/j.issn.1001-1978.2015.08.014
文献标志码:
A
摘要:
目的 探讨黄芪甲苷(ASIV)对链脲佐菌素(STZ)诱导的糖尿病大鼠心肌细胞能量代谢及线粒体合成的影响。方法 50只6周龄的SD大鼠,分为5组,每组10只,分别是空白组、模型组、ASIV 10、20、40 mg·kg-1组。除空白组,其余40只尾静脉注射STZ(35 mg·kg-1)建立Ⅰ型糖尿病心肌病模型。连续给药16周后,检测其左心室收缩压(LVSP)、左心室舒张期末压(LVEDP)、左心室最大上升/下降速率(±dp/dtmax),苏木精-伊红(HE)染色观察心肌病理切片。ELISA检测心肌组织中ATP、ADP、AMP的含量。Western blot法检测心肌组织中过氧化体增殖物激活型受体γ共激活因子1α(PGC-1α)和核呼吸因子(NRF-1)蛋白表达,RT-PCR检测心肌组织中PGC-1α和NRF-1 mRNA的表达。结果 与空白组相比,模型组大鼠的LVEDP上升,LVSP、±dp/dtmax下降, ATP/ADP、ATP/AMP比值均下降。与模型组相比,黄芪甲苷低剂量组变化不明显,中、高剂量组LVEDP下降,LVSP、±dp/dtmax上升, ATP/ADP、ATP/AMP比值均上升, PGC-1α与NRF-1的蛋白表达和mRNA表达均增加,有一定的剂量依赖性。结论 黄芪甲苷通过提高PGC-1α和NRF-1的表达促进Ⅰ型糖尿病大鼠心肌细胞内线粒体的生物合成,提高能量代谢。
Abstract:
Aim To investigate the effect of astragaloside IV(ASIV)on myocardial energy metabolism and mitochondrial biosynthesis in myocardial cells of diabetic rats induced by streptozotocin(STZ).Methods 50 SD rats at 6 weeks of age were assigned to 5 groups,10 for each group:control group, model group,ASIV 10 mg·kg-1·d-1 group, ASIV 20 mg·kg-1·d-1 group, ASIV 40 mg·kg-1·d-1 group. Except the control group,the remaining 40 were used to estab-lish type 1 diabetes model by the tail vein injection of STZ(35 mg·kg-1).At the end of 16 weeks of treatment, left ventricular systolic pressure(LVSP), left ventricular diastolic final pressure(LVEDP)and left ventricular maximum rising/falling rate(±dp/dtmax)were tested. Pathological section was observed by HE staining.ATP,ADP, AMP levels were detected by ELISA.The expressions of PGC-1α and NRF-1 protein were assessed by Western blot.The expressions of PGC-1α and NRF-1 mRNA were determined by RT-PCR. Results Compared with control group, model group markedly elevated LVEDP and decreased LVSP, ±dp/dtmax, ATP/AMP and ATP/ADP ratio. Compared with model group, low-dose ASIV group did not change significantly,middle-dose ASIV group and high-dose ASIV group obviously decreased LVEDP, and improved LVSP, ±dp/dtmax, ATP/ADP and ATP/AMP ratio. Meanwhile, the expressions of PGC-1α and NRF-1 protein and mRNA were increased in a dose-dependent manner. Conclusion ASIV could promote mitochondrial biosynthesis, improve energy metabolism in myocardial cells of type 1 diabetic rats by PGC-1α and NRF-1.

参考文献/References:

[1] Rowe G C,Jiang A,Arany Z. PGC-1 coactivators in cardiac development and disease [J]. Circ Res,2010,107(7):825-38.
[2] Aranv Z,He H,Lin J,et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contracrile function of cardiac muscle [J]. Cell Metab,2005,1(4):259-71.
[3] Sebastiani M,Giordano C,Nediani C,et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies [J]. J Am Coll Cardiol,2007,50(14):1362-9.
[4] Scarpulla R C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network [J].Biochim Biophys Acta,2011,1813(7):1269-78.
[5] 郭 茜,郭家彬,李 梨,彭双清. PGC-1α与线粒体O生成调控在心血管疾病中的作用[J].中国药理学通报,2013,29(1):1-5.
[5] Guo Q,Guo J B,Li L,Peng S Q. Role of PGC-1α and mitochondrial biogenesis in cardiovascular diseases [J]. Chin Pharmacol Bull,2013,29(1):1-5.
[6] 李香华,王洪新.黄芪甲苷在心血管疾病中的作用[J]. 心血管病学进展,2011,32(1):132-6.
[6] Li X H,Wang H X. Effect of astragaloside IV in cardiovascular disease [J]. Adv Cardiovasc Dis,2011,32(1):132-6.
[7] Diaz F,Moraes C T. Mitochondrial biogenesis and turnover[J],Cell Calcium,2008, 44(1):24-35.
[8] Pagel-Langenickel I,Bao J,Joseph J J,et al. PGC-lalpha integrates insulin signaling, mitochondrial regulation and bioenergetic function in skeletal muscle[J]. J Biol Chem,2008,283(33):22464-72.
[9] Wu Z,Puigserver P,Andersson U,et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1[J]. Cell,1999,98(1):115-24.
[10] Lin J,Handschin C,Spiegelman B M. Metabolic control through the PGC-1 family of transcription coactivators [J]. Cell Met,2005,1(6):361-70.
[11] Virbasius J V,Scarpulla R C. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis [J]. Proc Natl Acad Sci USA,1994,91(4): 1309-13.
[12] Garnier A,Fortin D,Delomenie C,et al. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles [J]. J Physiol,2003,551(Pt 2):491-501.
[13] Scarpulla R C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function[J]. Physiol Rev,2008,88(2):611-38.
[14] 张素萍,王洪新,栾爱娜,等.黄芪甲苷对异丙肾上腺素诱导大鼠心肌肥厚及过氧化物酶体增殖活化受体γ 辅助活化因子1α的影响[J].中药药理与临床,2014,30(3):65-8.
[14] Zhang S P,Wang H X,Luan A N,et al. Effect of astragaloside IV on myocardial hypertrophy and PGC-1α induced by isoproterenol in rats[J]. Pharmacol Clin Chin Mat Med,2014,30(3):65-8.
[15] Jiang B,Yang Y,Jin H,et al. Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNF-α in 3T3-L1 adipocytes[J]. Phytother Res,2008,22(11): 1434-9.
[16] 吕 琳. 黄芪甲苷对高脂加链脉佐菌素诱导的糖尿病小鼠的降血糖作用及其作用机制[D]. 广州:南方医科大学,2010.
[16] Lü L. Hypoglycemic effect and mechanisms of astragaloside IV in diabetic mice induced by high fat diet and streptozotocin[D]. Guangzhou:Southern Medical University,2010.

相似文献/References:

[1]柴丽娟,钟佩茹,周志焕,等.黄芪甲苷对体外神经干细胞增殖作用影响的研究[J].中国药理学通报,2010,(05):670.
 CHAI Li juan,ZHONG Pei ru,ZHOU Zhi huan,et al.Proliferation effects of astragaloside on neural atem cells in vitro[J].Chinese Pharmacological Bulletin,2010,(08):670.
[2]杜 强,张 倩,沈 立,等. 黄芪甲苷对慢性哮喘模型小鼠气道重塑的影响[J].中国药理学通报,2011,(10):1430.
 DU Qiang,ZHANG Qian,SHEN Li,et al. Effects ofAstragalosideⅣon airway rem odeling in a murine m odel of chronic asthm a [J].Chinese Pharmacological Bulletin,2011,(08):1430.
[3]王世博,邱景富,白群华,等.黄芪甲苷对H 2 O 2 致PC12细胞氧化应激损伤的保护作用[J].中国药理学通报,2011,(11):1603.
 WANG Shi-bo,QIU Jing-fu,BAIQun-hua,et al.A study on protection of astragaiosideⅣabout oxidative stress on PC12cells induced by H 2 O 2 [J].Chinese Pharmacological Bulletin,2011,(08):1603.
[4]王葳,姜燕,王巍巍,等.黄芪甲苷对脂肪源性干细胞体外生物学行为的影响[J].中国药理学通报,2013,(02):220.
 WANG Wei,JIANG Yan,WANG Wei wei,et al.Effects of Astragaloside IV on biological behavior of adipose tissuederived stem cells[J].Chinese Pharmacological Bulletin,2013,(08):220.
[5]李聪聪,陈春富,王爱武,等.大鼠脑缺血半暗带区外周型苯二氮卓受体的变化及黄芪甲苷的影响[J].中国药理学通报,2013,(06):846.
 LI Cong cong,CHEN Chun fu,WANG Ai wu,et al.Changes of PBRs in penumbra area after cerebral ischemiareperfusion injury and effects of astragaloside Ⅳ in rats[J].Chinese Pharmacological Bulletin,2013,(08):846.
[6]商蕾,曲章义,宁莉莉,等.黄芪甲苷体外抗腺病毒作用研究[J].中国药理学通报,2013,(06):854.
 SHANG Lei,QU Zhang yi,NING Li li,et al.The antiadenovirus effect of astragaloside IV in vitro[J].Chinese Pharmacological Bulletin,2013,(08):854.
[7]赵美眯,孙雪菲,连雯雯,等.黄芪甲苷对心肌细胞L型钙电流及细胞内钙的影响[J].中国药理学通报,2013,(10):1373.
 ZHAO Mei mi,SUN Xue fei,LIAN Wen wen,et al.Effects of astragaloside IV on Ltype calcium current and intracellular calcium concentration in cardiac myocytes[J].Chinese Pharmacological Bulletin,2013,(08):1373.
[8]黄小平,邓常清,邱咏园,等.黄芪甲苷和三七的三种有效成分配伍对小鼠脑缺血/再灌注后氧化应激和Nrf2/HO 1途径的影响[J].中国药理学通报,2013,(11):1596.
 HUANG Xiao ping,DENG Chang qing,QIU Yong yuan,et al.Effects of combinations of astragaloside Ⅳ and three active components in notoginseng on oxidative stress and Nrf2/HO1 pathway after cerebral ischemicreperfusion in mice[J].Chinese Pharmacological Bulletin,2013,(08):1596.
[9]贺永贵,李王芳,伊红丽,等.黄芪甲苷抑制GSK-3β活性介导大鼠心肌缺血/再灌注损伤作用的线粒体机制研究[J].中国药理学通报,2014,(03):402.
 HE Yong-gui,LI Wang-fang,YI Hong-li,et al.Mitochondrial mechanism of Astragaloside IV induced inhibition of GSK-3β in myocardial ischemia/reperfusion injury in rats[J].Chinese Pharmacological Bulletin,2014,(08):402.
[10]金华良,王利民,罗清莉,等.黄芪甲苷对Th2型淋巴细胞D10.G4.1体外作用的研究[J].中国药理学通报,2014,(11):1508.
 JIN Hua-liang,WANG Li-min,LUO Qing-li,et al.Effects of astragaloside IV on Th2 lymphocyte D10.G4.1 in vitro[J].Chinese Pharmacological Bulletin,2014,(08):1508.

备注/Memo

备注/Memo:
收稿日期:2015-03-26,修回日期:2015-04-29 基金项目:国家自然科学基金资助项目(No 81374008) 作者简介:曹琼丹(1990-),女,硕士,研究方向:心血管药理学,E-mail:cobra1129@163.com; 杨育红(1967-),女,博士,教授,研究方向:心血管药理学,通讯作者, E-mail:jzwangpeixun@163.com
更新日期/Last Update: 1900-01-01